Current Status of the Effectiveness of Infliximab with Crohn's disease-A prospective observational study of serum Infliximab consentrations
Not Applicable
- Conditions
- Crohn's disease
- Registration Number
- JPRN-UMIN000028343
- Lead Sponsor
- Kitasato University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Patients enrolled in other clinical trial pregnancy past history: cancer, malignancy serious infection tuberculosis allergy to medicine multiple sclerosis heart fairuler
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement rates 54 weeks after starting treatment with infliximab
- Secondary Outcome Measures
Name Time Method remission and improvement rates 14, 54 and 102 weeks after starting treatment with infliximab serum infliximab concentrations and ATI rates at these times correlations of serum infliximab concentrations with disease severity and the treatment response The rate of continuing treatment with infliximab side effect